Yonsei University Health System (YUHS) said Tuesday it created a research and development advisory center called ALYND to foster cooperation in the biopharmaceutical sector.
The center will work to bring together industry, hospital, and academic officials to work towards developing the biopharmaceutical industry, including cooperating in activities such as new drug development.
The hospital stressed the advisory center would provide advanced support services for industry-academia research collaboration through open innovation.
Open innovation will incorporate Severance Hospital’s know-how regarding clinical trials and the experience of YUHS’ Global Center for Clinical Trials established in 2013. The global center has provided consulting through its SALT PLUS services, a multidisciplinary medical consulting service, for more than 30 different cases within the past three years, according to YUHS.
"As in the case of foreign countries, the R&D Advisory Center will carry out the SALT PLUS program to cope with changes in the external environment, which will lead to various research cooperation between medical institution researchers and the industry through continuous promotional activities," Shim Jae-yong, head of the advisory center said.
Researchers and industry officials will have access to YUHS’ R&D resources through ALYND. The center will provide medical consulting regarding new drug and research development strategies. It will also provide analytical reports on medical research while opening academic conferences and symposiums for research cooperation between the industry, academia, and hospital.
The center will also provide analytical information on medical research upon completion of developing the Javis system, an innovative fusion clinical trial technology development project maintained by the Korea Clinical Trials Global Initiative and supported by the Ministry of Health and Welfare, YUHS said.
<© Korea Biomedical Review, All rights reserved.>